


All registrations, both for participants new to the study and those who are already in the study but are being re-registered to a new cohort, will count towards UK CRN accrual data.

**UK CRN ID: 7302.**

## Criteria for registration:



- **Patients who are new to the study:** Registration documents must be received at the study offices within 6 months of therapy start date.
- **Patients already registered who are switching to a new eligible therapy:** Re-registration paperwork must be received at the study offices as soon as possible, but within 24 months of the switch at the very latest.

## Currently accepting registrations for:

**Actemra/RoActemra** (tocilizumab)

**Benepali** (etanercept)

**Cimzia** (certolizumab)

**Enbrel\*** (etanercept)

**Erelzi** (etanercept)

**Flixabi** (infliximab)

**Humira\*** (adalimumab)

**Inflectra** (infliximab)

**Kevzara** (sarilumab)

**Olumiant** (baricitinib)

**Remicade\*** (infliximab)

**Remsima** (infliximab)

**Rixathon** (rituximab)

**Xeljanz** (tofacitinib)

\* Registrations for Humira, Enbrel and Remicade must be for biologic/biosimilar-naïve patients. Registrations for all other therapies do not have this requirement.

Registration forms available at [www.bsrbr.org](http://www.bsrbr.org)

**Have a question? Please contact us!** Tel: 0161 275 1652/7390

Email: [biologics.register@manchester.ac.uk](mailto:biologics.register@manchester.ac.uk) Twitter: @BSRBR\_RA